Publication | Closed Access

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Metabolic Associated SteatohepatitisHepatologyNonalcoholic Fatty Liver DiseaseLiver PhysiologyPharmacologyNon-alcoholic SteatohepatitisHepatotoxicityPharmacotherapyLiver DiseaseFatty Liver DiseaseMedicineDrug-induced Liver InjuryHealth Sciences